Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Summary

This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.

Timeline

Start

2015-03

Primary completion

2016-07

Completion

2017-01

Outcome

Outcome not reported

Stopped (Enrollment): “Slow Accrual”

Drugs

Indications